Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 15/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | MASP2 | O00187 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944319 | 0.89 | PTGER1 (0.45) | PTGER1MASP2F2 | |
| SCHEMBL2944068 | 0.87 | LMNA (0.49) | PTGER1TSHRPTGDR2MASP2F2 | |
| SCHEMBL4656398 | 0.86 | PTGER1 (0.52) | PTGER1PTGDR2MASP2F2 | |
| SCHEMBL2946766 | 0.86 | MAPT (0.58) | PTGER1TSHRPTGDR2F2 | |
| SCHEMBL2945768 | 0.84 | TSHR (0.48) | PTGER1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL2941158 | 0.84 | MEN1 (0.53) | PTGER1F2 | |
| SCHEMBL1332738 | 0.83 | TSHR (0.59) | PTGER1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL4910758 | 0.83 | PTGER1 (0.49) | PTGER1 | |
| SCHEMBL13603780 | 0.82 | TSHR (0.68) | PTGER1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL4626196 | 0.80 | MAPT (0.55) | PTGER1MASP2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678826-B2 | Organic compounds for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-03-16 | — | — | US | disclosed |
| EP-1891029-B1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20080200466-A1 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| EP-1891029-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | Novartis AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125596-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200466-A1 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions | HRH2, MRGPRX2, HRH1 | PTGER1 44/4885TSHR 450/4885HTR2A 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.